JP Morgan Chase
MRVI icon

JP Morgan Chase’s Maravai LifeSciences MRVI Stock Holding History

JP Morgan Chase’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
2,593,559
+2,236,299
+626% +$9.65M ﹤0.01% 2374
2026
Q1 		$1.03M Sell
357,260
-67,046
-16% -$227K ﹤0.01% 4592
2025
Q4 		$1.38M Buy
424,306
+154,509
+57% +$520K ﹤0.01% 4382
2025
Q3 		$774K Sell
269,797
-87,085
-24% -$222K ﹤0.01% 4764
2025
Q2 		$860K Sell
356,882
-321,305
-47% -$675K ﹤0.01% 4474
2025
Q1 		$1.5M Sell
678,187
-3,572,469
-84% -$14.1M ﹤0.01% 4070
2024
Q4 		$23.2M Buy
4,250,656
+200,411
+5% +$1.29M ﹤0.01% 1904
2024
Q3 		$33.7M Buy
4,050,245
+3,731,924
+1,172% +$32.3M ﹤0.01% 1597
2024
Q2 		$2.28M Sell
318,321
-158,451
-33% -$1.37M ﹤0.01% 3666
2024
Q1 		$4.13M Buy
476,772
+101,204
+27% +$685K ﹤0.01% 3256
2023
Q4 		$2.46M Buy
375,568
+55,828
+17% +$361K ﹤0.01% 3680
2023
Q3 		$3.2M Sell
319,740
-8,103
-2% -$89K ﹤0.01% 3180
2023
Q2 		$4.08M Sell
327,843
-3,562,634
-92% -$48.1M ﹤0.01% 3033
2023
Q1 		$54.5M Sell
3,890,477
-20,555
-0.5% -$295K 0.01% 1066
2022
Q4 		$56M Buy
3,911,032
+326,260
+9% +$5.14M 0.01% 1053
2022
Q3 		$91.5M Buy
3,584,772
+54,211
+2% +$1.36M 0.01% 765
2022
Q2 		$100M Buy
3,530,561
+135,961
+4% +$4.31M 0.01% 746
2022
Q1 		$120M Sell
3,394,600
-116,607
-3% -$3.91M 0.01% 769
2021
Q4 		$147M Sell
3,511,207
-455,348
-11% -$18.4M 0.02% 699
2021
Q3 		$195M Sell
3,966,555
-915,396
-19% -$44.7M 0.02% 583
2021
Q2 		$204M Buy
4,881,951
+498,314
+11% +$19.3M 0.02% 594
2021
Q1 		$156M Buy
4,383,637
+242,648
+6% +$8.04M 0.02% 657
2020
Q4 		$116M Buy
+4,140,989
New +$115M 0.02% 723

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

JP Morgan Chase's MRVI Position: Q2 2026 in Review

JP Morgan Chase increased its Maravai LifeSciences (MRVI) stake by 626% in Q2 2026, buying an estimated $9.65M and bringing the position to 2,593,559 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2374.

JP Morgan Chase first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $204M in Q2 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • JP Morgan Chase held 2,593,559 shares of Maravai LifeSciences worth $16.6M as of Q2 2026.
  • JP Morgan Chase bought 2,236,299 Maravai LifeSciences shares in Q2 2026, an estimated $9.65M.
  • Maravai LifeSciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2374 holding.
  • JP Morgan Chase first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Maravai LifeSciences position peaked at $204M in Q2 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.